BPC-157: Safety Profile & Research Summary
A partir de $40.95 · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo BPC-157 - todos os tamanhosResumo da Pesquisa Pre-clinica
Key Preclinical Studies
| Estudo | Modelo | Principais Achados | Ref |
|---|---|---|---|
| He et al. (2022) | SD rats / Beagle dogs | PK study: t½ = 15.2 min (rats), 5.27 min (dogs); biodisponibilidade 14-19% (rats), 45-51% (dogs); distributed to kidney, liver, stomach | [25] |
| Xu et al. (2020) | Mice, rats, rabbits, dogs | Multi-species toxicity: no adverse signs at 20 mg/kg (rats) or 10 mg/kg (dogs) | [9] |
| Staresinic et al. (2003) | Rats — Achilles transection | 10 µg/kg: melhorou AFI scores, aumentou load-to-failure at 14-72 days; reversed corticosteroid impairment | [16] |
| Tudor et al. (2010) | Mice — TBI | 10 µg/kg: reduziu brain edema, hemorrhage, and mortality; melhorou conscious/unconscious/death ratio | [18] |
| Perovic et al. (2019) | Rats — spinal cord | 200 µg/kg: axonal recovery manteve to 1 year; counteracted necrose, desmielinizacao, cyst formation | [19] |
| Vukojevic et al. (2020) | Rats — bilateral carotid occlusion | Upregulou Egr1/Akt1/Src/Vegfr2/Nos3; downregulou Nos2/Nfkb in hippocampus | [13] |
| Hsieh et al. (2017/2020) | Rat hind limb isquemia + CAM | 129–152% aumentou angiogenese; VEGFR2-Akt-eNOS pathway confirmou | [7] |
| Sever et al. (2019) | Rats — bile duct ligation | Fibrosis, portal-hypertension, liver-enzyme and bilirubin endpoints reported | [22] |
| Matek et al. (2025) | Rats — quadriceps detachment | Muscle-to-bone attachment and contracture endpoints reported at 90 days | [17] |
| Chang et al. (2011/2014) | Rat tendon fibroblastos (in vitro) | ↑ GHR expression, ativou FAK-paxillin pathway, aprimorou sobrevivencia celular and migration | [11][12] |
Parametros Farmacocineticos
| Parametro | Valor | Ref |
|---|---|---|
| Half-life (rats) | 15.2 minutes | [25] |
| Half-life (dogs) | 5.27 minutes | [25] |
| Bioavailability (rats) | 14–19% | [25] |
| Bioavailability (dogs) | 45–51% | [25] |
| Tmax (rats) | ~3 minutes | [25] |
| Major Metabolite | Proline (aminoacido) | [25] |
| Gastric Stability | >24 hours in human gastric juice | [3] |
| Urine Detection | 4–5 days via LC-MS | [25] |
Os produtos oferecidos neste site são fornecidos apenas para estudos in vitro. Estudos in vitro (do latim: em vidro) são realizados fora do corpo. Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença. A introdução corporal de qualquer tipo em humanos ou animais é estritamente proibida por lei.
Apenas para Pesquisa Laboratorial. Não se destina ao uso humano, uso médico, uso diagnóstico ou uso veterinário.
TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
“Resumo da Pesquisa Pre-clinica Key Preclinical Studies EstudoModeloPrincipais AchadosRef He et al.”
Referencias
- Sikiric P, et al. A novo(a) gastric juice peptide, BPC. An overview do(a) stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology-Paris. 1993;87(5):313-327.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response. Current Pharmaceutical Design. 2020;26(25):3024-3044.
- U.S. Food and Drug Administration. Certain Substancia Farmaceutica a Granels for Use in Compounding que May Present Significant Safety Risks. FDA.gov. Updated 2023.
- World Anti-Doping Agency. The 2025 Lista de Substancias Proibidas. WADA. January 1, 2025.
- Ruenzi M, et al. Gastroenterology. 2005;128(Suppl 2):A-585.
- Hsieh MJ, et al. Journal of Molecular Medicine. 2017;95(3):323-333.
- Sikiric P, et al. Current Pharmaceutical Design. 2025.
- Xu C, et al. Regulatory Toxicology and Pharmacology. 2020;114:104665.
- Hsieh MJ, et al. BPC157 aprimora the hormonio do crescimento receptor expression in tendon fibroblastos. Molecules. 2020;25(21):5159.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing envolve tendon outgrowth, sobrevivencia celular, and migracao celular. Journal of Applied Physiology. 2011;110(3):774-780.
- Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.
- Vukojevic J, et al. Rat inferior caval vein (ICV) ligature and BPC 157. Molecular Neurobiology. 2020;57:4029-4044.
- Sikiric P, et al. O(a) farmacologico(a) properties do(a) novel peptide BPC 157. Inflammopharmacology. 1999;7(1):1-14.
- Zemba Cilic A, et al. Stable gastric pentadecapeptide BPC 157 and dopamine system. Current Neuropharmacology. 2021;19(11):1696-1714.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 acelera healing of transected rat Achilles tendon e em vitro estimula tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983.
- Matek D, et al. Biomedicine & Pharmacotherapy. 2025.
- Tudor M, et al. Regulatory Peptides. 2010;160(1-3):26-32.
- Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of lesao medular. Journal of Orthopaedic Surgery and Research. 2019;14:440.
- Sikiric P, et al. Vascular occlusion and estavel gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2022;28(25):2082-2093.
- Masnec S, et al. Stable gastric pentadecapeptide BPC 157 heals corneal injuries. Current Pharmaceutical Design. 2015;21(33):4868-4875.
- Sever M, et al. Stable gastric pentadecapeptide BPC 157 counteracts liver fibrose. Journal of Physiology and Pharmacology. 2019;70(3):391-400.
- Lee E, Padgett B. Alternative Therapies in Health and Medicine. 2021.
- Lee E, Walker C, Ayadi B. Alternative Therapies in Health and Medicine. 2024.
- He Y, et al. Pharmacokinetics and excrecao study of BPC157 in rats and dogs. Journal of Chromatography B. 2022;1201:123300.
- Veljaca M, et al. Gut. 2003;52(Suppl VI):A246.
- Lee E, Burgess K. Alternative Therapies in Health and Medicine. 2025.
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: GI Tract Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989.
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo BPC-157 - todos os tamanhos→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
